Cargando…

TP53 mutation influences the efficacy of treatment of colorectal cancer cell lines with a combination of sirtuin inhibitors and chemotherapeutic agents

Chemoresistance of colorectal cancer (CRC) leads to tumor recurrence and metastasis and new strategies are urgently needed to improve the outcomes of conventional chemotherapy. Sirtuin (SIRT) inhibitors prevent tumor cell growth by increasing the levels of acetylated histones and non-histones, as we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Hao, Chen, Ya, Jiang, Yuan, Wang, Dongliang, Yan, Jun, Zhou, Zhaoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388297/ https://www.ncbi.nlm.nih.gov/pubmed/32742376 http://dx.doi.org/10.3892/etm.2020.8818

Ejemplares similares

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/−) and TP53(−/−) cells
por: Willis, Alexandra J., et al.
Publicado: (2018)

TP53 mutations in Romanian patients with colorectal cancer
por: Manirakiza, Felix, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Hyperthermia Enhances Efficacy of Chemotherapeutic Agents in Pancreatic Cancer Cell Lines
por: Maurici, Costanza E., et al.
Publicado: (2022)

Schistosoma mansoni Sirtuins: Characterization and Potential as Chemotherapeutic Targets
por: Lancelot, Julien, et al.
Publicado: (2013)

TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy
por: Noor, Humaira, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin
por: Wang, Quan, et al.
Publicado: (2013)

Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis
por: Pan, Da, et al.
Publicado: (2013)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism
por: Clarke, Stephen L., et al.
Publicado: (2019)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells
por: Webster, Peter John, et al.
Publicado: (2017)

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
por: Schimmer, Roman R., et al.
Publicado: (2022)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition
por: Nucera, Silvia, et al.
Publicado: (2020)

Comparing ion torrent with pyrosequencing and Sanger sequencing for the detection of TP53 mutations in colorectal cancer
por: Doyle, Brendan, et al.
Publicado: (2014)

Association of intron microsatellite status and exon mutational profiles of TP53 in human colorectal cancer
por: Liu, Xin, et al.
Publicado: (2019)

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines
por: Chappell, William H., et al.
Publicado: (2020)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

TP53 mutations on circulating cell-free DNA
por: Pantel, Klaus
Publicado: (2016)

Germline mutation in the TP53 gene in uveal melanoma
por: Hajkova, Nikola, et al.
Publicado: (2018)

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

A novel TP53 pathway influences the HGS-mediated exosome formation in colorectal cancer
por: Sun, Yulin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ip47m70k0j4arip2g5osq4fdp3